Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
GAITHERSBURG, Md., Nov. 08, 2017 -- Novavax, Inc., (Nasdaq:NVAX) today announced the Company will present at the Stifel 2017 Healthcare Conference.
Presentation details are as follows:
Date: Wednesday, November 15, 2017
Time: 1:15 p.m. – 1:55 p.m. ET
Location: Garrison, 5th Floor, Lotte New York Palace Hotel, New York City
Live webcast: www.novavax.com, “Investors”/“Events”
A replay of the presentation will also be accessible under the “Investors/Events” section of the Novavax website at novavax.com.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.
Contact:
Investor Relations
Novavax, Inc.
Andrea N. Flynn, Ph.D.
Director, Investor & Media Relations
[email protected]
240-268-2000
Westwicke Partners
John Woolford
[email protected]
443-213-0506
Media
Russo Partners, LLC
David Schull
Maggie Beller
[email protected]
[email protected]
212-845-4271
